MDM2 and neuroblastoma: Our findings revealed that two anti-histaminedrugs, CZ and RP, exhibited a robust affinity toward the p53-bindingsite of MDM2 in silico and anti-proliferative activity on both U87glioblastoma and SHSY5Y neuroblastoma cell lines in vitro.